Indian generics giant Ranbaxy Laboratories is setting up a second plant in Malaysia.
The company says it will invest about $40 million and will employ about 200 people at the facility. The plant will make tablets and capsules, primarily for cardiovascular, anti-diabetic, anti-infective and gastrointestinal treatments.
The company says in a release that its total output in Malaysia will be increased from 1 billion doses to 3 billion doses a year when the new facility is fully operational.
It already has a plant in Sungai Petani, Kedah, Malaysia, built in 1987, which has more than 300 workers. Ranbaxy Malaysia Sdn. Bhd. is a joint venture company of Ranbaxy Laboratories and Malaysian shareholders. It was formed in 1982.
India is considered one of the best markets in the world for making generic drugs, and is attracting a lot of interest from branded drugmakers. Companies, however, are scouting Asia for opportunities to build plants where costs are lower and to serve growing markets in that part of the world.
- here's the release
Special Report: Top Emerging CRO Markets